A New Drug Specifically for Patients with Bronchiectasis

Brensocatib lowered the incidence of exacerbations in the trial that led to FDA approval.

In August 2025, the U.S. FDA approved brensocatib (Brinsupri) for the treatment of non–cystic fibrosis bronchiectasis in adults and children 12 years of age and older. Two doses are available: 10 mg and 25 mg.

Context Anatomic, infectious, and immunologic factors contribute to the development and progression of bronchiectasis, but one common pathway for structural damage is the release of proteases by neutrophils. Brensocatib inhibits the activation of these proteases and is the first drug specifically approved by the FDA to reduce the incidence of bronchiectasis exacerbations.

Supporting Data In the trial that led to FDA approval, 1700 patients with bronchiectasis and at least two antibiotic-treated exacerbations during the previous year w…

Authors

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Gerald L. Weinhouse, MD

Disclosures

Nothing to disclose

Gerald L. Weinhouse, MD

Disclosures

Nothing to disclose

A New Drug Specifically for Patients with Bronchiectasis

Topics

Authors